My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Radiat Oncol. 2007 Aug 26;2:31.

    No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro.

    Hermann RM, Schwarten D, Fister S, Grundker C, Rave-Frank M, Nitsche M, Hille A, Thelen P, Schmidberger H, Christiansen H.

    Department of Radiotherapy, University hospital, Göttingen, Germany. ro.hermann@t-online.de

    BACKGROUND: Oncological results of radiotherapy for locally advanced prostate cancer (PC) are significantly improved by simultaneous application of LHRH analoga (e.g. goserelin). As 85% of PC express LHRH receptors, we investigated the interaction of goserelin incubation with radiotherapy under androgen-deprived conditions in vitro. METHODS: LNCaP and PC-3 cells were stained for LHRH receptors. Downstream the LHRH receptor, changes in protein expression of c-fos, phosphorylated p38 and phosphorylated ERK1/2 were analyzed by means of Western blotting after incubation with goserelin and irradiation with 4 Gy. Both cell lines were incubated with different concentrations of goserelin in hormone-free medium. 12 h later cells were irradiated (0 - 4 Gy) and after 12 h goserelin was withdrawn. Endpoints were clonogenic survival and cell viability (12 h, 36 h and 60 h after irradiation). RESULTS: Both tested cell lines expressed LHRH-receptors. Changes in protein expression demonstrated the functional activity of goserelin in the tested cell lines. Neither in LNCaP nor in PC-3 any significant effects of additional goserelin incubation on clonogenic survival or cell viability for all tested concentrations in comparison to radiation alone were seen. CONCLUSION: The clinically observed increase in tumor control after combination of goserelin with radiotherapy in PC cannot be attributed to an increase in radiosensitivity of PC cells by goserelin in vitro.

    PMID: 17718927 [PubMed]

    PMCID: PMC2034383

    Supplemental Content

    Click here to read Click here to read
    Write to the Help Desk